US Patent

US8440170 — Orally disintegrating tablets with speckled appearance

Formulation · Assigned to Alpex Pharma SA · Expires 2029-03-14 · 3y remaining

Vulnerability score 60/100 Moderate — design-around opportunities exist

What this patent protects

This patent protects orally disintegrating tablets with a speckled appearance, made with colored granules of a water-soluble sugar.

USPTO Abstract

Orally disintegrating tablets containing colored granules of a water-soluble sugar which give them a speckled appearance are described. The orally disintegrating tablets with speckled appearance are readily and easy identifiable by physicians, nurses and patients.

Drugs covered by this patent

phentermine-hydrochloride (PHENTERMINE HYDROCHLORIDE)

Patent Metadata

Patent number: US8440170
Jurisdiction: US
Classification: Formulation
Expires: 2029-03-14
Drug substance claim: No
Drug product claim: Yes
Assignee: Alpex Pharma SA
Source: FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.